Form 4: Coeptis Therapeutics Director Christopher Cochran Receives Stock Options

Director Christopher Cochran received a grant of 5,700 non-qualified stock options in Coeptis Therapeutics Holdings, Inc.

Summary

• Christopher Cochran, a director of Coeptis Therapeutics Holdings, Inc., received a grant of 5,700 non-qualified stock options on March 4, 2025.
• These options were granted under the company's 2022 equity incentive plan.
• The exercise price is $10.56, which is the fair market value (FMV) of the shares on the grant date.
• The options vest in four equal installments over one year, starting on March 31, 2025, and ending on December 31, 2025.
• The options expire ten years from the grant date.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a routine disclosure of stock option grants.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director.
• Employees may see this as a standard compensation practice.

Key Dates